Get all your news in one place.
100's of premium titles.
One app.
Start reading
Axios
Axios
Health

Hyped weight loss drugs raise supply, equity concerns

Buzz from celebrities and social media influencers around the off-label use of diabetes drugs for weight loss is prompting a spike in prescriptions and concerns about cost and possible shortages.

The big picture: More than 5 million prescriptions were written for Novo Nordisk's Ozempic or Eli Lilly's Mounjaro for weight management in 2022, up from about 230,000 in 2019, per Komodo Health.


Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.